BIO-PATH HOLDINGS, INC.
BPTH evidence brief
What we can confirm
- BioSniper Score:
- 4.1 / 10
- Market Cap:
- $10K
- Lead Asset:
- BP1001 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for BPTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BPTH
Bio-Path Holdings is a clinical-stage biotechnology company developing RNAi nanoparticle therapies for oncology and obesity, using its DNAbilize® platform to achieve systemic delivery of antisense drugs.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$10K
Cash Runway
—
Lead Asset
BP1001 (Phase 2)
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates for BIO-PATH HOLDINGS, INC..
Bio-Path Holdings is a clinical-stage biotechnology company developing RNAi nanoparticle therapies for oncology and obesity, using its DNAbilize® platform to achieve systemic delivery of antisense drugs.
- Bio-Path is a clinical and preclinical stage oncology- and obesity-focused RNAi nanoparticle drug development company using its DNAbilize® platform [sec_mda · as of 2026-05-20].
- The company's lead drug candidates include prexigebersen, BP1002, BP1003, and BP1001-A, targeting cancer and other diseases [sec_mda · as of 2025-08-14].
- As of March 31, 2025, Bio-Path had an accumulated deficit of $120.4 million and reported a net loss of $2.9 million for the three months ended March 31, 2025 [sec_mda · as of 2025-05-15].
- On June 5, 2026, UT MD Anderson Cancer Center agreed to restart Phase 2 trials for AML (BP1001-201-AML and BP1002-201-AML) subject to payment of $292,264.21 and $63,286.55 respectively [sec · filed 2026-07-16].
- The company is developing a molecular biomarker package to accompany prexigebersen treatment to identify patients more likely to respond [sec_mda · as of 2026-05-20].
What works
- The DNAbilize® platform uses a P-ethoxy DNA backbone modification and neutral lipid bilayer, which may enable high-efficiency loading and systemic delivery of antisense drugs [sec_mda · as of 2026-05-20].
- Bio-Path is expanding its pipeline beyond oncology into obesity and autoimmune disorders, potentially broadening its market opportunity [sec_mda · as of 2025-08-14].
- The company is developing a molecular biomarker package to improve the probability of success for prexigebersen by identifying responsive patient profiles [sec_mda · as of 2026-05-20].
What to weigh
- Bio-Path has an accumulated deficit of $120.4 million as of March 31, 2025, and expects to continue incurring significant operating losses [sec_mda · as of 2025-05-15].
- The company's Phase 2 AML trials were paused due to monies owed to MD Anderson, and restart is contingent on payment of over $355,000 [sec · filed 2026-07-16].
- Shareholders' equity was negative $8.5 million as of March 31, 2026, indicating a weak balance sheet [sec].
- There are no assurances that the company's efforts to manage finances, perform acquisitions, or improve capital structure will be successful [sec · filed 2026-07-16].
From the filings
Quoted directly from source documents.
MD Anderson agreed to restart Phase 2 AML trials subject to payment of outstanding amounts.
“On June 5, 2026, UT MD Anderson cancer center ("MDA" @ https://www.mdanderson.org/) agreed to restart our Phase 2 trials targeting acute myeloid leukemia (AML) subject to us bringing them current on monies due of $292,264.21 for BP1001-201-AML and $63,286.55 for BP1002-201-AML.”
SEC filings · July 16, 2026
Accumulated deficit of $120.4 million as of March 31, 2025.
“As of March 31, 2025, we had an accumulated deficit of $120.4 million.”
SEC MD&A · May 15, 2025
Bio-Path is developing a biomarker package for prexigebersen.
“We are developing a molecular biomarker package to accompany prexigebersen treatment, the goal of which is to identify patients with a genetic profile more likely to respond to the investigational treatment and improve the probability of success for this program as a result.”
SEC MD&A · May 20, 2026
Risks & what to watch (4)›
Key risks
- Negative shareholders' equity — Shareholders' equity was -$8.5M as of 2026-03-31, indicating a weak financial position [sec].
- Clinical trial restart dependent on payment — Phase 2 AML trials at MD Anderson require payment of >$355K to restart; no guarantee of funding [sec · filed 2026-07-16].
- Accumulated deficit and ongoing losses — Accumulated deficit of $120.4M as of 2025-03-31; net loss of $2.9M for Q1 2025 [sec_mda · as of 2025-05-15].
- Uncertainty of strategic initiatives — No assurances that efforts to manage finances, perform acquisitions, or improve capital structure will succeed [sec · filed 2026-07-16].
What to watch
- Whether Bio-Path can secure funding to pay MD Anderson and restart Phase 2 AML trials [sec · filed 2026-07-16].
- Progress of the molecular biomarker package for prexigebersen and its impact on trial design [sec_mda · as of 2026-05-20].
- Any updates on the company's expansion into obesity and autoimmune indications [sec_mda · as of 2025-08-14].
- Financial results and cash runway updates in future SEC filings, given the negative equity position [sec].
Sources: SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run BIO-PATH HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIO-PATH HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$38K · Net income -$270K
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2025Institutional holders
2
Total value held
$5K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 31,127 | $5K |
| jones financial companies lllp | 1 | $0 |
Short Interest
as of May 20, 2026- % of float
- 1.4%
- Days to cover
- 0.4
- Shares short
- 79,346
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BPTH short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIO-PATH HOLDINGS, INC.?
Bio-Path Holdings is a clinical-stage biotechnology company developing RNAi nanoparticle therapies for oncology and obesity, using its DNAbilize® platform to achieve systemic delivery of antisense drugs.
What is BIO-PATH HOLDINGS, INC.'s lead drug candidate?
BIO-PATH HOLDINGS, INC.'s most advanced tracked candidate is BP1001 (Phase 2) for Acute Myeloid Leukemia (AML).
Who is the CEO of BIO-PATH HOLDINGS, INC.?
Mr. Vikram Paul Grover C.F.A., Esq. is the chief executive officer of BIO-PATH HOLDINGS, INC. (BPTH).
Where is BIO-PATH HOLDINGS, INC. headquartered?
BIO-PATH HOLDINGS, INC. (BPTH) is headquartered in Bellaire, TX, United States.
What therapeutic areas does BIO-PATH HOLDINGS, INC. focus on?
BIO-PATH HOLDINGS, INC. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.